Join us either virtually or in-person at the Health Tech Hub, University of the West of England (UWE) for a short talk from Santorini Scientific Research Scientist Stephanie Restivo, followed by informal networking.
Teas, coffees & pastries will be provided :-)
Company Bio: Santorini’s mission is to drive and implement medical advances which will allow heart transplant patients to live their lives to the fullest. Heart transplants are often the only available treatment for patients with end-stage heart failure, with more than 8000 taking place every year worldwide. Though the short-term success rate of heart transplants is now high, long term clinical outcome remains unacceptable, with the majority of allografts surviving approximately 10 years.
We have identified the following three streams to improve quality of life for heart transplant patients:
3D Bioprinting the world’s first transplantable human heart
Using T Cell Therapy to achieve allograft tolerance
Early modelling and detection of rejection.
Santorini Scientific is led by Mike Adams, an entrepreneur and visionary with over 35 years of experience in research and new technologies, including considerable depth of expertise in the pharmaceutical and hospital sectors. He has worked with organisations including Spire Health Care, Hertfordshire Health Authority, Pfizer, Uni-Chem and Medicare. Cardiac bioprinting for transplant purposes requires an interdisciplinary team with expertise in a variety of different fields.
Santorini Scientific is working to overcome the challenge of ensuring knowledge is shared between disciplines, in order to achieve its ambitious goal of 3D bioprinting the world’s first transplantable human heart, which can only be accomplished through collaboration.
Santorini Scientific | Stephanie Restivo, Research Scientist
Speaker Bio: Stephanie Restivo is Biological Sciences graduate form the University of Exeter. She is a founding member of Santorini Scientific, an SME which focuses on improving quality of life for heart transplant patients, and has been co-developing the company for the past three years.